Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Oakridge Global Energy Solutions, Inc. (OGES) Ushering in a New Era in Battery Manufacturing

Lithium ion batteries are more widely used than ever before. To illustrate this fact, consider the recent rise in production by Tesla Motors, Inc. (NASDAQ: TSLA), the automotive company behind a line of luxury electric cars, electric vehicle powertrain components and other battery products. Following the launch of its $5 billion Gigafactory focused on improving traditional lithium ion batteries, Tesla expects to have the ability to produce more lithium ion batteries each year than were manufactured worldwide in 2013, according to a report from Fox Business.

This sharp increase in production capacity will likely be met with an equally strong rise in demand. Leading global research firm Research and Markets forecasts the industry sustaining a compound annual growth rate of 14.4 percent in the seven year period ending 2019, leading to a global market value in excess of $33.1 billion. While major industry players such as Tesla are making advances toward bringing the benefits of this growth back to the United States, a large majority of currently-available lithium ion batteries and related products are imported from factories in China and Southeast Asia.

The dangers of substandard lithium ion batteries are well documented. Despite the fact that roughly 30 percent of the 5.5 billion cell phone batteries produced each year are shipped by air, according to a report by the Insurance Journal, an increasing number of passenger and freight airlines – including both United Airlines (NYSE: UAL) and Delta (NYSE: DAL) – have taken steps to ban bulk shipments of lithium ion batteries following reports that these storage solutions contributed to fires that destroyed two Boeing (NYSE: BA) 787 cargo planes in 2014. While the exact cause of these fires has yet to be identified, the National Transportation Safety Board openly criticized Boeing and its battery manufacturer for the faults.

In a 2013 article ( published by Forbes, contributor Steve Denning summarized one potential issue observed in the manufacturing process of the Boeing 787.

“Some degree of outsourcing in other countries—i.e. offshoring—is an inevitable aspect of manufacturing a complex product like an airplane, because some expertise exists only in foreign countries. For example, the capacity to manufacture Lithium-ion batteries lies outside the U.S.,” Denning stated in the article. “While there is nothing in principle wrong with necessary offshoring, the cultural and language differences and the physical distances involved in a lengthy supply chain create additional risks. Mitigating them requires substantial and continuing communications with the suppliers and on-site involvement, thereby generating additional cost.”

This practice of offshoring lithium ion battery manufacturing has led to additional quality and safety concerns in recent months. During the final months of 2015, hoverboards were established as the go-to gift for the holiday season. However, improperly manufactured lithium ion batteries and substandard quality control transformed this futuristic gift into a nightmare for dozens of families around the globe (

Oakridge Global Energy Solutions, Inc. (OTCQB: OGES) is taking a proactive approach to combatting the dangers of some internationally-produced stored energy products by commercializing a full line of ‘Made in the USA’ lithium ion battery solutions. The company’s products – including its Pro Series, Patriot Series, Freedom Series and Liberty Series – are designed, manufactured and tested to strict standards directly from its state-of-the-art manufacturing facilities in Brevard Country, Florida. In the coming months, Oakridge expects to install more than 2.6 gigawatt-hours of production capacity for U.S.-manufactured electrodes, cells and batteries, creating an affordable, competitive product that gives families and businesses an opportunity to support the local economy.

With an experienced management team in place and a detailed company roadmap outlining plans to increase its presence in the rapidly expanding lithium ion battery market, Oakridge is well-positioned to usher in a new era in battery manufacturing as a leader in the ongoing ‘on-shoring’ movement. Look for the company to continue expanding upon its product line in the coming months in an effort to promote strong, sustainable returns for shareholders.

For more information, visit

Posted in Oakridge Global Energy Solutions Inc. OGES | Leave a comment

Content Checked Holdings, Inc. (CNCK) Nutritionist Contributes Health and Wellness Tips in Z Living Article

Content Checked Holdings, Inc. (OTCQB: CNCK) continued to make progress toward increasing awareness of its innovative suite of mobile apps last week when it was named in an article published on Z Living, a leading network for health and wellness programming. In the article, titled “Foods That Sneak Sugar Into Your Weight-Loss Meal Plan,” author Menaka Warrier examines the effects of cutting out sugar when attempting to shed a few pounds. Victoria Brodsky, head of nutrition for Content Checked, contributed helpful advice regarding the true benefits of sugar-free and low-fat foods.

In the article, Brodsky warns that “sugar-free foods lure us with the prospect of eating sweets and maintaining that waistline, but over-indulging in them can be counterproductive… Their unnatural makeup of delivering sugar without the calories promotes metabolic dysfunction which causes you to store fat and leads to an increase in appetite.” Along with this advice, the article features a link to a selection of posts on the Content Checked website which provides additional information about limiting sugar intake and promoting a healthier lifestyle.

To view the full article, visit

Z Living is dedicated to showcasing the best of healthy lifestyle and wellness entertainment across multiple mediums – including television, the internet and on-demand streaming networks. The network’s website attracts an audience of more than 36,000 unique month visitors with a regularly updated selection of articles focusing on beauty, fitness, food and healthy lifestyle inspiration.

In recent weeks, Content Checked has leveraged the marketability of its suite of nutrition-based mobile apps – including ContentChecked, MigraineChecked and SugarChecked – to secure coverage in an assortment of popular blogs and news sites. Through these efforts, in addition to a planned rebranding of its products to be unveiled in the coming weeks, the company aims to increase its market share while continuing to improve the lives of individuals with specific dietary preferences or food-related allergies.

For more information, visit

Posted in ContentChecked Holdings Inc. CNCK | Leave a comment

OncBioMune Pharmaceuticals, Inc. (OBMP) Preparing to Commence Phase II Clinical Study of ProscaVax™ Cancer Vaccine

OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products. The company’s lead product candidate, ProscaVax™, is a novel prostate cancer vaccine that’s scheduled to commence a phase II clinical trial in the coming weeks after recording promising results in its phase I clinical trial, which was completed late last year.

Unlike many leading treatment options, ProscaVax is being developed to treat prostate cancer in its early stages, allowing patients to build up an immunity that helps their bodies combat the disease with little or no toxicity. OncBioMune’s revolutionary technology introduces molecules known as antigens into the body in order to stimulate an aggressive immune response before the cancer becomes too advanced. In its phase I clinical trial of ProscaVax, an impressive 70 percent of patients who received three vaccines demonstrated increased immune response to prostate-specific antigen (PSA), a protein produced by cells of the prostate gland that can aid in the early detection of prostate cancer. This result, in addition to the candidate’s exemplary safety profile, bodes well for ProscaVax moving forward.

Leveraging a proprietary vaccine technology designed to boost the immune system’s natural ability to protect the body, ProscaVax is expected to be marketable and extremely profitable upon FDA approval, potentially becoming the standard of care for prostate cancer treatment. According to data from the American Cancer Society, about 220,800 new cases of prostate cancer were diagnosed in the United States last year. In total, the disease accounts for more than 27,500 deaths each year, making it the second leading cause of cancer death in American men.

Despite its prevalence, prostate cancer remains one of the most survivable forms of cancer, with a 10-year survival rate of roughly 98 percent in cases discovered in the local or regional stages. However, survivability is greatly impacted if the disease goes undetected into an advanced stage. In cases where prostate cancer has spread to bones, organs or distant lymph nodes, the five-year survival rate drops from nearly 100 percent to just 28 percent, according to ZERO. This statistic further highlights the potential benefit of ProscaVax, particularly in early stage prostate cancer cases.

Leading market research firm BCC Research valued the global market for the prevention and treatment of prostate cancer at $26.1 billion in 2011, and the firm forecasts the market to surpass $50 billion by next year. This growth will be led by the drug therapeutics sector, which is expected to sustain an 18 percent compound annual growth rate through 2017. As OncBioMune prepares to commence its phase II clinical trial of ProscaVax, this market performance could foreshadow an opportunity for the company to achieve strong financial growth following FDA approval and commercialization of its innovative treatment option.

Through an agreement with Lincoln Park Capital Fund, OncBioMune has secured $10 million in funding with which to help finance the upcoming phase II clinical study of ProscaVax. This strong cash position, along with the early promise of the company’s cancer vaccine technologies, makes OncBioMune an attractive play in the rapidly evolving oncology space.

For more information, visit

Posted in Small Cap News | Leave a comment

Content Checked Holdings, Inc.’s (CNCK) SugarChecked App Featured in Article on #LatinaGeeks

Content Checked Holdings, Inc. (OTCQB: CNCK), the company behind the innovative ContentChecked, MigraineChecked and SugarChecked mobile applications, has made tremendous strides toward increasing its brand awareness in recent months by contributing helpful tidbits for living a healthier life in articles on some of the web’s top nutrition- and technology-focused news sites. Earlier this week, the company built on this progress when SugarChecked, an app that identifies four main types of sugars in products with a quick and easy barcode scan, was featured in an in-depth review article by social media and technology news site #LatinaGeeks.

In the review, Tanya M. Salcido, a #LatinaGeeks contributor, takes a closer look at the benefits of using the SugarChecked app, which she refers to as “having your own team of specialists in the palm of your hands.” After quickly discussing some of the biggest advantages of using Content Checked’s convenient shopping assistant – including the option to set personalized dietary suggestions, receive multiple healthy alternatives to sugary products and search through a database of nutritional recipes – Salcido added an impressive list of standout features offered in SugarChecked, including the fact that it is now free to download in both Google Play and the App Store.

To view the full article, visit

Founded in 2013, #LatinaGeeks is an influential site within the Hispanic community. Its target audience is made up primarily of early adopters, social media enthusiasts, entrepreneurs, influencers, branding experts, marketing pros, Web 2.0 aficionados and technology addicts. The site has a strong social media presence – including thousands of likes and followers on Facebook and Twitter.

By continuing to secure coverage in popular media outlets, Content Checked is progressing toward its goal of uplisting to the NASDAQ or NYSE in the coming months. In a letter to shareholders, Kris Finstad, chairman and chief executive officer of Content Checked, highlighted uplisting to a major exchange as a primary goal for the company in 2016. As part of this effort, Content Checked plans to unveil a relaunch and rebrand of its products in March, introducing a new, subscription-based revenue model designed to meet the evolving preferences of its growing user base.

For more information, visit

Posted in ContentChecked Holdings Inc. CNCK | Leave a comment

Lightlake Therapeutics, Inc. (LLTP) Targeting Addictions and Related Disorders with Platform of Innovative Intranasal Naloxone Solutions

Lightlake Therapeutics, Inc. (OTCQB: LLTP) is a specialty pharmaceutical company engaged in the development of pharmacological treatments for substance abuse, addiction and eating disorders. In December 2014, the company entered into a global licensing deal with a subsidiary of Adapt Pharma Limited to develop and commercialize Lightlake’s innovative intranasal naloxone opioid overdose reversal treatment, NARCAN® Nasal Spray. As per the terms of this deal, Lightlake could receive potential development and sales milestone payments totaling more than $55 million – including a $2 million milestone payment following FDA approval and a $2.5 million milestone payment following the first commercial sale of NARCAN in the U.S. – in addition to double-digit royalty fees.

In November 2015, NARCAN was approved by the U.S. Food and Drug Administration for the emergency treatment of known or suspected opioid overdose. This approval marked the first time that naloxone –the trusted choice of healthcare providers to reverse the effects of opioid overdose for more than 40 years – was approved for distribution in the U.S. in a non-injection delivery method. Since its approval, momentum to increase access to naloxone has been on the rise. Late last year, President Obama included a call to make naloxone more readily available as part of a major initiative to address the nation’s opioid epidemic.

The commercial potential of NARCAN, to be marketed by Adapt, is expansive. In 2013, opioid overdose related deaths claimed nearly 24,500 lives in the U.S., accounting for roughly 52 percent of all drug overdose deaths, according to the Centers for Disease Control and Prevention. In total, prescription opioid abuse costs accounted for approximately $55.7 billion in 2007, with about 45 percent of all spending attributed to healthcare expenses.

In addition to its efforts to address the domestic opioid crisis, Lightlake has also completed a phase II clinical trial for its naloxone nasal spray to treat binge eating disorder (BED), a condition resulting in a lack of control when eating foods that are high in sugar, fat or salt. According to clinical data, the company’s nasal spray is well-suited to treating BED because it remains in the brain for two hours – the duration of a typical binge – without inducing negative side effects, such as a loss of interest in exercise, which are common with long-lasting opioid antagonists like naltrexone and nalmefene. Lightlake has also announced plans to conduct a Cocaine Use Disorder study in collaboration with the National Institute of Drug Abuse in the future.

With President Obama allocating $133 million toward the opioid epidemic in 2016 and guidelines from the Department of Health suggesting that naloxone could eventually become a standard script accompanying the more than 240 million opioid prescriptions written every year in the U.S., Lightlake, through its licensing deal with Adapt, is well positioned to record strong financial growth in the months to come. Look for the company to benefit from royalties stemming from this licensing agreement as it continues to advance its promising clinical pipeline targeting the treatment of BED and cocaine use disorder.

For more information, visit

Posted in Small Cap News | Leave a comment

Content Checked Holdings, Inc. (CNCK) Empowers Consumers

After a triumphant initial launch of its ContentChecked app, Content Checked Holdings, Inc. (OTCQB: CNCK) is looking ahead. The company has set its sights on a wider release of its ContentChecked app and its other apps (SugarChecked and MigraineChecked) in order to further its impact.

What problem is Content Checked interested in solving? The company is developing smartphone applications for use by U.S. residents suffering from food allergies and intolerances, as well as migraine and chronic headaches. In the years since its establishment in 2013, the California-based company has conceived and introduced the ContentChecked, MigraineChecked and SugarChecked smartphone apps to the public and, as a result, created an innovative marketplace for people with dietary restrictions and the institutions who cater to them.

Content Checked continues to leverage and promote the effectiveness of its current apps, including its most recent addition, SugarChecked. How exactly does SugarChecked work? SugarChecked is an easy shopping tool for consumers who are interested in decoding often-misleading food labels and receiving recommendations for healthier alternative products in real time as they shop.

The app, which is available in the iPhone App Store and Google Play Store, allows consumers to use their smartphones to scan the barcode on a food item. It then highlights the sugar content of that item and the forms sugar will take if it is consumed. The app specifically identifies the four main types of sugars that consumers can avoid, including added sugars, artificial sweeteners, natural low-calorie sweeteners and sugar alcohols, and all of this comprehensive sugar content information is fact checked by a team of nutritionists. Then, if the item is unsuitable for the user, based on his or her dietary preferences, the app suggests a host of alternatives from an extensive food database.

SugarChecked empowers consumers. It gives them the ability to scan the barcodes of grocery store products and determine what kind of sugars they contained. It also educates them on their options and why they may want to avoid certain food items. In doing this, the app is geared toward meeting the needs of millions of people in the United States who suffer from dietary restrictions, wish to maintain a low sugar diet and want to avoid unwelcome, hidden ingredients.

In addition to serving consumers, SugarChecked also serves food producers. It has given food producers a vital way to showcase their products to consumers who are actively seeking those types of products, and it does so at the point of purchase.

For more information, visit

Posted in ContentChecked Holdings Inc. CNCK | Leave a comment

Torchlight Energy Resources, Inc. (TRCH) is “One to Watch”

Torchlight Energy Resources, Inc. (NASDAQ: TRCH) is a high growth oil and gas Exploration and Production (E&P) company primarily focused on the acquisition and development of highly profitable domestic oil fields. Leveraging a diverse portfolio, carefully selected interests, and a strong management team are pillars of Torchlight’s broader success strategy.

The company maintains a diversified energy portfolio by holding interests in numerous projects in multiple established plays, and it currently holds interests in Texas, Oklahoma and Kansas, where its targets are established plays such as the Wolf Penn, Eagle Ford Shale, Mississippi Limestone and Hunton Limestone trends.

Torchlight is currently moving forward on the next phase of drilling on three new wells in its Orogrande Project in West Texas, where the company owns a 47.5% working interest on 168,000 acres alongside Founders Oil and Gas, LLC. Torchlight drilled the Rich A-11 well (6,091 feet) on the Orogrande Project in March last year and subsequently executed a $50 million JV farm-out agreement with Midland, Texas-based Founders Oil and Gas, who initiated frac work on the well in November.

The Marcelina Creek Project in South Texas, with its prime access to the Austin Chalk, Buda, and Eagle Ford formations, is surrounded on all four sides by leading Eagle Ford producers. Torchlight’s Johnson #4 well was recently re-entered and drilled laterally to approximately 2500 feet in the Austin Chalk Formation. With more than 20 additional drilling locations on its Marcelina Creek Asset, the project has the potential to positively impact cash flows and production sustainability.

Torchlight’s executive team and board of directors are led by CEO John Brda and COO Willard McAndrew III. Combined they have over 50 years of experience in the oil and gas industry as executives, investors and consultants to the industry. Their knowledge base includes all aspects of the business, including: operations, mid stream, capital formation, purchase and sale of assets, re-entries, investor relations and oil and gas consulting for public and private companies.

Key Investment Highlights:

  • Defined strategy targets highly profitable oil fields in the United States
  • Diversified energy portfolio enables projects in multiple established plays
  • Primary focus on interest in major Orogrande Basin discovery in West Texas
  • Strong management team with vast, relevant experience in energy industry

For more information on the company, visit

Posted in Torchlight Energy Resources, Inc. TRCH | Leave a comment

Stellar Biotechnologies, Inc. (SBOT) Releases Financial Results for Fiscal Quarter Ended December 31, 2015

On Monday, Stellar Biotechnologies, Inc. (NASDAQ: SBOT) (TSX-V: KLH), the leader in the sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), announced its financial results for its first fiscal quarter ended December 31, 2015. According to the report, the company successfully leveraged the increased visibility and improved access to institutional investors provided by its recent uplisting to the NASDAQ Capital Market (completed on November 5, 2015) to drive a 130 percent year-over-year increase in quarterly revenue.

“We are pleased to report good momentum heading into 2016, with what we believe are positive indicators for our core KLH business,” Frank Oakes, president, chief executive officer and chairman of Stellar, stated in the news release. “We are focusing on continuing to increase sales revenue, and we are working to expand our commercial and clinical opportunities with new collaborations.”

One such collaboration was proposed on January 20, 2016, in the form of a joint venture between Stellar and Neovacs, S.A, a leading biotechnology firm focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. The purpose of this proposed joint venture is to produce Neovacs’ Kinoid product candidates using Stellar’s KLH. The term sheet also outlined the possibility of manufacturing other KLH-based immunotherapies on behalf of third party customers in the future. As of writing, this proposed joint venture has yet to be consummated.

Additional highlights from Stellar’s financial report include:

  • The company generated total revenues of $488,160 for the three months ended December 31, 2015, compared to $212,661 for the three months ended December 31, 2014
  • Total expenses for the quarter were $1.8 million, compared to $1.5 million for the same period in 2014; the company attributed this increase to a combination of NASDAQ listing fees, compensation increases, increased share-based compensation and increased investor relations activity
  • Stellar’s working capital as of December 31, 2015, was $8.97 million, compared to working capital of $7.49 million as of September 30, 2015
  • The company maintained positive shareholders’ equity of $9.6 million and approximately 8.45 million shares outstanding as of December 31, 2015, compared to shareholders’ equity of $8.0 million and approximately 7.98 million shares outstanding at September 30, 2015

To view the full financial report, visit

Stellar has applied decades of specialized aquaculture science to a pharmaceutical industry challenge, creating the only KLH production facility of its kind in the world and establishing itself as the world leader in the sustainable manufacture of this important immune-stimulating molecule. The company’s customers and partners include multinational pharmaceutical companies, renowned research centers, and developers of active immunotherapies and therapeutic vaccines.

For more information, visit and

Posted in Small Cap News | Leave a comment

International Stem Cell Corp. (ISCO) Eyes Growth through Partnerships to Develop Therapeutic and Biomedical Products Worldwide

International Stem Cell Corp. (OTCQB: ISCO) builds shareholder value through the development of restorative medicine using stem cell technology. Through its innovative parthenogenesis technology, the company makes use of human stem cells from unfertilized oocytes (eggs), bypassing common ethical controversy that accompanies the destruction of the viable human embryo. Additionally, the company works with subsidiaries Lifeline Skin Technology and Lifeline Skin Care in the area of skin rejuvenation on a product that contains a nano-compound that facilitates the replenishment of the skin’s texture and elasticity.

Evidence of the company’s resolve to be a leader in the field of restorative medicine can be found in a recent partnership with The Florey Institute of Neuroscience and Mental Health, one of the world’s leading brain research centers. The agreement calls for the team to launch Phase I/IIa clinical trials research on the effects of human parthenogenetic stem cells in people with Parkinson’s disease.

The credibility The Florey Institute brings to ISCO’s mission to build shareholder value cannot be understated. The Florey Institute of Neuroscience and Mental Health is one of the world’s leading brain research centers, employing a staff of over 500. The center’s scientists comprise the largest neuroscience research team in Australia. Its work is conducted on a range of serious diseases, including stroke, epilepsy, Alzheimer’s disease, Parkinson’s disease, traumatic brain and spinal cord injury, depression, multiple sclerosis, Huntington’s disease, motor neuron disease, schizophrenia, mental illness and addiction. Further, The Florey is viewed by many as a world leader in imaging technology, stroke rehabilitation and epidemiological studies.

The company’s human cell culture products are made up of adult stem cells and reagents for regenerative medicine aiding in the study of prostate disease, human renal and bladder diseases, human corneal cells present in corneal disease and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. ISCO markets and sells skincare products through its website, channel sales, distributors and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corp. was founded in 2001 and is headquartered in Carlsbad, California.

For more information, visit

Posted in International Stem Cell Corp. ISCO | Leave a comment

Torchlight Energy Resources, Inc. (TRCH) Moving Forward with Planning of Next Phase of Drilling on Orogrande Project

Earlier today, Torchlight Energy Resources, Inc. (NASDAQ: TRCH) announced that the Orogrande Development Committee, which consists of members of the project operator, Torchlight and consulting geologist Rich Masterson, has elected to move forward on planning the next phase of drilling in the Orogrande Project. Following this decision, the project operator is expected to permit three new wells, beginning with the University Founders B-19 #1 well, to be drilled vertically for test purposes. These new wells will be designed with sufficient casing size to support lateral entry into any pay zones encountered during testing – including pay zones previously observed in the existing Cactus well.

“We are pleased that the project operator is underway on next steps in evaluating our Orogrande Project,” Will McAndrew III, chief operating officer of Torchlight, stated in the news release. “Drilling additional test wells is the appropriate next action, providing data necessary for validation of the play and the development plan for the entire 168,000 acres. Our principal strategy is to create control data by strategically placing wells across the acreage and thus creating a development thesis for the entire basin.”

Field operations stemming from this agreement are set to begin within 90 days and in line with the development agreement. Last September, Torchlight announced entry into a definitive agreement with Founders Oil and Gas, LLC of Midland, Texas, through which Founders will contribute $50 million in development capital by 2017 – including a $5 million reimbursement for initial project costs – in exchange for 50 percent working interest in the Orogrande Project. Following the commencement of new drilling operations, Torchlight will receive a payment of $500,000 resulting from this partnership.

“The capital and expertise being provided by our operating partner has set the stage for continued value creation for Torchlight and our shareholders,” concluded McAndrew.

Currently, Torchlight owns 95 percent working interest in the 168,000 acre Orogrande Project, which is located in Hudspeth County, Texas. The company is targeting 1,300 feet of pay at a depth of approximately 4,000 to 6,100 feet. In prior testing, Torchlight utilized the Rich A-11 well to gather key data for its field development thesis, but a poor cement bond discovered during testing prevented a cost-effective production test of the project’s primary pay zones. Repairing these defects was determined to be economically unfeasible, and, as a result, the development committee approved plans for drilling of the next wells with larger casings that can be utilized for both testing and commercial production moving forward.

For more information on the company, visit

Posted in Torchlight Energy Resources, Inc. TRCH | Leave a comment